Vicore has carried out a directed share issue of 10,000,000 shares at a subscription price of SEK 20 per share, raising gross proceeds of SEK 200 million

/PRNewswire/ -- Vicore Pharma Holding AB (publ) ("Vicore" or the "Company"), a pioneer in the development of angiotensin II type 2 receptor agonists (ATRAGs),...

Related Keywords

Australia ,Japan ,United States ,New Zealand ,Hong Kong ,Stockholm ,Sweden ,United Kingdom ,Singapore ,South Africa ,Canada ,Swedish ,Van Lanschot Kempen ,Carl Johan Dalsgaard ,Neither The Company ,Fourth Swedish National Pension Fund ,Prnewswire Vicore Pharma Holding ,Baker Mckenzie ,Financial Services ,Carnegie Investment Bank ,European Union Withdrawal ,Vicore Pharma Holding ,Commission Delegated Directive ,Pareto Securities ,Zonda Partners ,Joint Bookrunners ,Nasdaq Stockholm ,Directed Issue ,Invus Public Equities ,Medical Strategy ,Swedbank Robur Fonder ,Cicero Fonder ,Johan Dalsgaard ,Prospectus Regulation ,Member State ,European Union ,Markets Act ,Financial Promotion ,Securities Act ,Nasdaq First North Growth Market ,Governance Requirements ,Target Market Assessment ,Pharma Holding ,Vicore Pharma Holding Ab ,Health Care Amp Hospitals ,Medical Pharmaceuticals ,Pharmaceuticals ,Accounting News Amp Issues ,